baber/WOPTO huggingface dataset:
Patent NZ-507607-A (NZ)
Title: Method of producing a transgenic plant by transforming witha 1-SST enzyme (sucrose:surcose 1-fructosyltransferase) and/or a 1-FFT enzyme (fructan:fructan 1-fructosyltransferase)
Inventor: DE LEENHEER LENA
IPC: C12N15/29
Filed: 1999-04-15
Abstract: A transgenic plant with a modified inulin producing profile comprises in its genome a combination of one or more expressible 1-SST (sucrose: sucrose 1-fructosyltransferase) enzyme encoding genes and one or more expressible 1-FFT (fructan: fructan 1-fructosyl-transferase) enzyme encoding genes. Either the 1-SST enzyme encoding genes or the 1-FFT enzyme encoding genes or both comprise one or more recombinant genes containing one or more 1-SST enzyme encoding expressible a33 cDNA sequences according to SEQ ID NO:1, or one or more 1-FFT enzyme encoding expressible c86b cDNA sequences according to SEQ ID NO:3 respectively. The plant can be produced by transforming a host plant by inserting one or more of the 1-SST enzyme encoding genes and/or 1-FFT enzyme encoding genes into the genome of the host plant. A method for producing inulin from the plant and uses of the inulin are described. Also described is the use of the polypeptides of SEQ ID NO:2 and 4 as catalyst in the in vitro synthesis of 1-kestose and oligofructoses from sucrose.
Patent NZ-511599-A (NZ)
Title: Synthesis of a fast cure phenol-formaldehyde that eliminates the need for the synergistic effect of surfactants
Inventor: COLLINS PETER JAMES
IPC: C08G8/10
Filed: 1999-11-25
Abstract: A process for producing a phenol formaldehyde resin having a phenolate core of high alkalinity and methylol end groups of lower alkalinity is described.  The process includes forming a phenolate by reacting a phenol with a phenolate-forming agent and reacting the phenolate with formaldehyde under conditions which promote a methylolation reaction rather than a condensation polymerisation reaction.  Favourable conditions include a molar ratio of formaldehyde to phenol in excess of 2:1 and a reaction temperature in a range from 50 to 70 DEG C.  Phenolate forming agents include sodium hydroxide and potassium hydroxide.
Patent NZ-520312-A (NZ)
Title: Hyaluronic acid in the treatment of cancer
Inventor: PHILLIPS NIGEL
IPC: A61K35/74
Filed: 2000-12-28
Abstract: Composition and method comprising purified HA, a second anti-neoplastic agent and a pharmaceutically acceptable carrier, wherein the purified HA and the second anti-neoplastic agent are administered to a mammal having cancer in an amount effective to treat the cancer.
Patent NZ-521079-A (NZ)
Title: Hyaluronic acid gel, process for producing the same, and medical material containing the same
Inventor: KAWATA MASATOSHI
IPC: A61L31/04
Filed: 2000-02-03
Abstract: Production of a hyaluronic acid gel, which comprises keeping hyaluronic acid in water at a hyaluronic acid concentration of at least 5 wt% in the presence of an acid component in an amount at least equimolar with the carboxyl groups in hyaluronic acid. A biomedical material containing a hyaluronic acid gel made of hyaluronic acid alone that has transparency and dissolves in a neutral aqueous solution at 25C is also disclosed.
Patent NZ-521867-A (NZ)
Title: Purine derivatives
Inventor: MANTELL SIMON JOHN
IPC: A61P11/00
Filed: 2001-06-14
Abstract: Purine compounds of formula (I) are disclosed, for which the substituents are defined herein. The compounds are used in the manufacture of medicaments for the treatment of a disease for which an A2a receptor agonist is indicated.
Patent NZ-524020-A (NZ)
Title: Articulated jib crane
Inventor: YERLY JEAN-MARC
IPC: B66C23/10
Filed: 2001-07-10
Abstract: The crane consists of a pylon (21) with a jib foot (31) pivoted to its tip by one end (35) and having the jib (41) articulated to its other end (36). The jib has its tip (43) on one side of its pivot point (45) and a counter-jib (42) on the other, and the jib is retained by an assembly with one or more posts (16), a tie member (25) and at least one two-way power cylinder connecting the foot and jib. The foot and counterjib are designed to allow the jib tip to be aligned with the foot.
Patent NZ-524428-A (NZ)
Title: Cap closure
Inventor: VON SPRECKELSEN HENNING
IPC: B65D51/20
Filed: 2003-02-26
Abstract: A closure comprising a neck and cap assembly for use with a container having a body, where the neck and cap assembly comprises a base closed by a foil and adapted to be fitted to the body. The closure also comprises a removable annular flange (30) connected to a pull ring (42) and secured to the foil, where the removable annular flange (30) being separated from the base by a frangible region and a plurality of depending teeth each having a saw tooth profile inclined inwardly to a centre of the base formed in the base in or adjacent to the frangible region such that on removal of the pull ring (42) the foil is torn by the teeth.
Patent NZ-525113-A (NZ)
Title: Manufacture of paper and paperboard
Inventor: CHEN GORDON CHENG I
IPC: D21H17/68
Filed: 2001-10-04
Abstract: A process for making paper of paper board comprising forming a cellulosic suspension, flocculating the suspension, draining the suspension on a screen to form a sheet and then drying the sheet, characterised in that the suspension is flocculated using a flocculation system comprising a siliceous material and organic microparticles which have an unswollen particle diameter of less than 750 nanometers. A further flocculating material is included into the cellulosic suspension before adding the polymeric microparticles and siliceous material. The further flocculating material is cationic and is a natural or synthetic polymer.
Patent NZ-525819-A (NZ)
Title: Ozone/UV combination for the decomposition of endocrinal substances
Inventor: RIED ACHIM
IPC: B01D24/02
Filed: 2002-09-09
Abstract: A method for the treatment of water in the simultaneous presence of pathogenic germs and at least one difficultly degradable substance from the group containing persistent substances, endocrinal substances, odorous substances and dyes, in particular the treatment of waste water or drinking water with ozone supply and UV irradiation, the method comprising the steps of: (a) the addition of ozone in a concentration of 0.1 g/m3 to 15g/m3 (b) degasification of the water; and (c) irradiation of the degasified water with UV radiation in a wavelength ranging from 200nm to 300nm and in a dose ranging from 50 J/m2 to 2,000 J/m2; a waste water treatment device; and the use of the device for reducing the content of endocrinal substances in drinking water or in waste water.
Patent NZ-526218-A (NZ)
Title: Agent for treating allergic or hypersensitivity condition
Inventor: WILLIAMS NEIL ANDREW
IPC: A61K38/16
Filed: 1999-01-08
Abstract: The use of an agent selected from Etx, Ctx, EtxB or CtxB in the manufacture of a medicament for use in the treatment and/or prevention of an allergic condition and/or a hypersensitivity condition, such as asthma, allergic cough, allergic rhinitis, conjunctivitis, atopic eczema, dermatitis, uticaria, hives, insect bit allergy, dietary allergy, drug allergies or contact hypersensitivity, wherein the agent is not coupled to the antigen; and a pharmaceutical composition comprising an agent selected from Etx, Ctx, EtxB or CtxB and a pharmaceutically acceptable carrier, diluent or excipient wherein the agent is not coupled to an antigen. (62) Divided out of 505181
Patent NZ-528047-A (NZ)
Title: Methods and compositions for masking the taste of pharmaceutically active agents
Inventor: FAVARA ANDREW J
IPC: A61K9/16
Filed: 2002-02-04
Abstract: Methods and compositions for reducing the perception of poor-tasting pharmaceutically active agents in the oral cavity or for masking the unpleasant taste of pharmaceutically active agents are disclosed. Particles containing one or more pharmaceutically active agents, flavorants and cellulosic materials, as well as methods for making same and for incorporating same into pharmaceutical dosage forms are also disclosed. In certain embodiments, the particles have a diameter of up to about 1000 micrometers and include the pharmaceutically active agent, a flavorant, and at least one cellulosic material that is microcrystalline cellulose, microcrystalline cellulose coprocessed with a hydrocolloid, or any combination thereof, individually or in admixture with a hydrocolloid.
Patent NZ-528307-A (NZ)
Title: Spattering apparatus
Inventor: COTTIER JOHN SYDNEY
IPC: C09D201/00
Filed: 2002-03-01
Abstract: An apparatus (1) for applying a slurry to a substrate (2). The apparatus includes a delivery drum (4) incorporating a delivery surface (5) disposed to support a layer of slurry. A spattering roller (8) is positioned closely adjacent the delivery drum and is rotatable so as to spatter the slurry from the delivery surface onto the substrate. Regulation means selectively vary or interrupt vary or interrupt the flow of slurry from the delivery surface onto the substrate.
Patent NZ-531058-A (NZ)
Title: Method and apparatus for identifying components of a system with a response characteristic
Inventor: KIIVERI HARRI
IPC: G16B40/00
Filed: 2002-07-11
Abstract: A method for identifying components of a system from data generated from the system, which exhibit a response pattern associated with a test condition applied to the system, comprises specifying design factors to specify a response pattern for the test condition and identifying a linear combination of components from the input data which correlate with the response pattern.
Patent NZ-531748-A (NZ)
Title: Diagnostic assay for vasculature by measuring multiple biological markers
Inventor: CHRISTOPHERSON RICHARD IAN
IPC: G06F19/00
Filed: 2001-09-12
Abstract: A method for stratifying a subject on the basis of having experienced a prior event of the vasculature (acute) or having not experienced a prior event of the vasculature is described. The method comprises contacting a sample from the subject which comprises members associated with an event of the systemic vasculature with one or more binding partners of the members. The binding partners are immobilized to a solid support and the pattern of interaction between the members and the binding partners provides an assessment of the presence or absence or actual level or change in level of the event of the systemic vasculature such that an elevated level of at least seven members is indicative of an acute condition wherein no change in levels of the members is indicative of a subject not having experienced a prior event of the vasculature. The members are selected from .myoglobin, myosin light chain, myosin heavy chain, total creatine kinase, creatine kinase-MB, lactate dehydrogenase, aspartate aminotransferase, cardiac troponin I and T, fatty acid binding protein (FAB protein), glycogen phosphorylase-BB isoenzyme, alpha-atria natriuretic peptide, brain natriuretic peptide, adrenomedullin, low density lipoprotein, very low density lipoprotein, high density lipoprotein and intermediate density lipoprotein, C reactive protein, serum amyloid A, P-selectin, prostaglandins, platelet-activating factor, histamine, tumor necrosis factor alpha, soluble TNF receptor 2, fibrin, fibrinogen, fibronolytic peptides, modified haemoglobin, ferritin, soluble intercellular adhesion molecule (ICAM) including soluble intercellular adhesion molecule-1(ICAM1), heat shock proteins, apoB, apoA, apoE, homocysteine or parts thereof, Streptococcus sp., Porphyromonas gingivalis, Helicobacter pylori and Chlamydiapneumoniae or immunological relatives thereof, necrosis and platelet markers, leptin, vasopeptidase inhibitor of cardiac endogenous kinins, heparin, metalloproteinase-9, metalloproteinase-1 including its tissue inhibitor, angiotensin-converting enzyme, CD95/Apo1/Fas, hepatocyte growth factor, soluble vascular cell adhesion molecule-1, plasma brain natriuretic peptide, angiotensin II type receptor, endothelial constitutive nitric oxide synthase, glycoprotein IIIa genetic polymorphisms, factor VIIa, thrombin, endothelin-1, cardiac myofibrillar proteins, Fas and Fas ligand, ligands thereof or binding partners thereof or nucleic acid molecules encoding same or their fragments or ligands or binding partners. Also described is an array of binding partners and a method for determining the presence or absence of a condition or event of the systemic vasculature.
Patent NZ-531889-A (NZ)
Title: Solids/liquids separator
Inventor: PHILLIPS DONALD IAN
IPC: E03F5/14
Filed: 2001-05-11
Abstract: A separator for separating solids and other objects form a liquid, said separator having a separator body through with the liquid, having debris entrained therein, flows from an inlet to an outlet, and means for diverting flow from the outlet during moderate flows whereby the solids and other objects entrained in the liquid is removed, and wherein the means for diverting the flow is an opening in the separator and has adjacent thereto a wall containing a plurality of apertures therethrough, and wherein at low liquid fluid flow acquires potential energy that is converted to velocity energy as it falls through the opening and down the apertured wall to impact on the water surface in a lower chamber causing violent agitation against the said apertured wall thus maintaining the apertures free of blockages by solid bodies.
Patent NZ-534681-A (NZ)
Title: A database entity
Inventor: BOYES PAUL ANDREW
Filed: 2004-08-13
Abstract: A computer system is programmed to have and running a computer database. The database consists of five tables each having an entity identifier field (RSNE). The first table is configured so that it has or can accommodate one or more parent entity identifier fields (P0-N RSN). The first table is also configured so that it has or can accommodate one or more additional fields used for accessing data by way of indexes, sort orders, or non-secured data. The second table has an unique identifier field (RSN) and is configured so that it has or can accommodate one or more further data fields (value 0 .N) for holding free form data, not limited to a selection from a list of allowed values. The third table has an unique identifier field (RSN) and is configured so that it has or can accommodate one or more unique identifier fields for a value of a single valued data item (V0 .N RSN) wherein the item is limited to one data value from a list of allowed values. The fourth table has an unique identifier field (RSN) and is configured so that it has or can accommodate one or more unique identifier fields for a multi valued data item (F0 .N RSN). The fifth table has an unique identifier field (RSN), an unique identifier field for a multi valued data item (F RSN) for a field in the fourth table and an unique identifier field for a value of a multi valued data item (V RSN). The database is configured such that the entity identifier field (RSNE) of the first table is in a one to one relationship with the entity identifier field (RSNE) of each of the second, third and fourth tables and at the same time the entity identifier field (RSNE) of the first table is in a one to many relationship with the entity identifier field (RSNE) of the fifth table and at the same time if present, each unique identifier field (F0 .N RSN) for the multi valued data item in the fourth table is in a one to many relationship with the unique identifier field (F RSN) for a multi valued data item of the fifth table.
Patent NZ-537934-A (NZ)
Title: Multiple applicators
Inventor: TSAUR GARRY
Filed: 2003-10-24
Abstract: A multiple applicators comprising an elongated housing that is separated into multiple sealed compartments containing a liquid and an applicator tip with a score line formed at each of the sealed compartments located near the applicator tip wherein the elongated housing may be selectively severed into shorter sections at the score lines and removed. The removed section of the elongated housing is used to apply the liquid or viscous substance contained therein and disposed of after application. The remainder of the elongated housing with the remaining unused applicator tips and liquid is retained for subsequent uses.
Patent NZ-540091-A (NZ)
Title: Animal cleaning apparatus
Inventor: RAMSEY FRANCIS JOHN
Filed: 2005-05-17
Abstract: An animal cleaning apparatus suitable for cleaning animals while they are supported on, and being transported by, a conveyor means. The apparatus is arranged and configured such that it is able to move at least one cleaning device in a first direction substantially parallel to the direction of travel of the conveyor means and in a second direction substantially at right angles to the direction of travel of the conveyor means. Preferably the apparatus includes a shroud which is adapted to at least partially contain any matter that is removed from an animal and to prevent the spread of that material to adjacent animals.
Patent NZ-540729-A (NZ)
Title: Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors
Inventor: CRESCENZI BENEDETTA
IPC: C07D221/00
Filed: 2003-12-18
Abstract: Disclosed are tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of formula (I), which are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1 or 2, and R1, R3, R4, R12 and R14 are defined as defined in the specification. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Patent NZ-540930-A (NZ)
Title: Enhanced surface coverings, yarns and methods
Inventor: BRIDGES JAMES C
IPC: D06N7/00
Filed: 2003-12-12
Abstract: A process for forming a carpet, and the carpet formed thereby are provided. The process includes forming a thread comprising low melt fiber and high melt fiber. The thread is then heated above a temperature sufficient to melt the low melt fiber. The thread is tufted in a carpet backing to form a tufted carpet. The tufted carpet is then printed or dyed with an image. A process for forming a low melt content yarn and the yarn formed thereby are provided.
Patent NZ-545764-A (NZ)
Title: Amino-substituted ethylamino B2 adrenergic receptor agonists
Inventor: LINSELL MARTIN S
IPC: C07D215/38
Filed: 2004-09-21
Abstract: Disclosed is a compound of formula (I) wherein the substituents are defined within the specification or a pharmaceutically-acceptable salt or solvate or stereoisomer thereof. Also disclosed is a method of preparing a compound of formula (I). Also disclosed is using the compound of formula (I) for manufacturing a medicament for the treatment of a disease or condition associated with beta2 adrenergic receptor activity such as a pulmonary disease or condition.
Patent NZ-551153-A (NZ)
Title: Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
Inventor: YUN SANGMIN
IPC: C07D498/02
Filed: 2004-10-18
Abstract: Disclosed is crystalline clopidogrel naphthalenedisulfonate of formula (1b) or hydrates thereof and methods of making them and pharmaceutical compositions containing them.
Patent NZ-555413-A (NZ)
Title: Compressor improvements
Inventor: BOYD JOHN H
Filed: 2003-05-30
Abstract: A compressor having a single cylinder with an enclosed end defining a compression space, with a piston reciprocating in the single cylinder, comprising a plurality of gas flow paths from the compression space to a discharge space, a self operating valve in each gases flow path, opening under the influence of the prevailing pressure differential across the valve, and being biased to a closed condition by a spring, each of the valves and springs being part of a single unitary planar valve member.
Patent NZ-565005-A (NZ)
Title: Process for the preparation of sulfonamide derivatives
Inventor: GLADWELL IAIN ROBERT
IPC: C07C51/09
Filed: 2006-07-10
Abstract: Disclosed is a process for the preparation of a compound of formula (I) wherein Q1 is a group selected from formula (a) or (b) and a group *NR6QzA, wherein the symbol * represent the attachment point to the carbonyl group, QZ is a C1-C4 alkylene optionally substituted, R6 is Hydrogen or C1-C4 alkyl and A is pyridyl optionally substituted with OH, C3-C7 cycloalkyl optionally substituted with OH, or a group of formula (c) or (d) or, if appropriate, their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof, comprising the use of a compound of formula (7).
Patent NZ-575943-A (NZ)
Title: Improvements in or Relating to Medicament Delivery Devices
Inventor: SUTHERLAND GARTH CAMPBELL
Filed: 2009-04-01
Abstract: A reusable and portable communications device is disclosed. The device is intended for receiving and transmitting data relating to patient usage of an electronic medicament delivery device. The electronic medicament delivery device includes: a supply of medicament, a medicament dispensing means, and data gathering means for gathering data relating to patient usage of the electronic medicament delivery device. The communications device includes: a housing able to be releasably fitted to the electronic medicament delivery device, data collection means associated with the housing to receive data from the electronic medicament delivery device, and a wireless communicator associated with the housing to enable the wireless transmission of said data.
Patent NZ-578750-A (NZ)
Title: Putative cytokinin receptor and methods for use thereof
Inventor: KUMAR PRAKASH PALLATHADKA
IPC: C12N15/29
Filed: 2008-02-05
Abstract: Disclosed is a method of modulating the expression of at least one trait in a plant, the method comprising the step of modulating the expression of at least one polypeptide in the plant, wherein the polypeptide is selected from the group consisting of: i) a polypeptide which comprises the amino acid sequence according to SEQ ID NO:1; ii) a polypeptide which comprises an amino acid sequence which is selected from the group consisting of anyone or more of from amino acid 9 to amino acid 230, from amino acid 1 to amino acid 58, from amino acid 77 to amino acid 485, from amino acid 59 to amino acid 76, from amino acid 231 to amino acid 405, and from amino acid 406 to amino acid 438 of SEQ ID NO: 1, and which is capable of modulating cytokinin signaling in the plant; iii) a polypeptide which comprises an amino acid sequence with at least 70% sequence identity to the amino acid sequence according to SEQ ID NO:1 and which is capable of modulating cytokinin signaling in the plant; and iv) a polypeptide which consists of an amino acid sequence according to SEQ ID NO:1, wherein the modulation of the expression of the polypeptide modulates the expression of at least one trait in the plant, wherein the at least one trait in a plant is selected from the group consisting of anyone of plant height, plant biomass, apical bud development, branching, fertility, flowering, leaf area, senescence, seed germination, seed yield, seed weight, stem development, grain yield, tiller number, floral meristem development and root development, and wherein the step of modulating the expression of the polypeptide comprises decreasing the expression of the polypeptide.